Bioverse EP7: The Essential Role of Commercialization | 药时代直播间

Dr. Hui Huang is an accomplished biopharma executive with over 20 years of cross-functional expertise spanning R&D, commercial strategy, and global market access. She currently serves as Founder and CEO of CSD Partners, advising biotech and pharma clients on aligning development strategies with regulatory and payer needs in the US, EU, and China to enable successful market access and product launches.

Prior to founding CSD Partners, Dr. Huang held various leadership roles at Millennium, ARIAD and most recently as Vice President of Global Value and Access at Takeda Pharmaceuticals. She received multiple awards for transforming Takeda’s development approach, leading to the smooth approval and global uptake of brands including VELCADE, ADCETRIS, NINLARO, ICLUSIG, ALUNBRIG, and MEPACT. She also played an instrumental role in valuations and negotiations for Takeda’s licensing deals and acquisitions across the US, Europe, and Asia Pacific.

Leveraging her passion for optimizing clinical programs and pricing strategies, Dr. Huang now works closely with emerging biotech companies to align global development and commercialization plans with regulatory and payer expectations across key geographies early in the pipeline. She holds an MBA from Yale University, a PhD in Biology from Syracuse University, and a BS from the University of Science and Technology of China.

As co-founder and CEO of Rapid Commercialization Partners (RCP), Christina is deeply inspired to build a legacy of innovation for how biotech companies approach commercialization, improving rates of success and impacting the lives of patients with rare or poorly managed disease worldwide. Strongly committed to the values of purpose, integrity and accountability, Christina has a proven record of building exceptional teams who work efficiently together in an environment supported by trust and professional respect that become highly productive and drive value across an organization.

Christina is a dynamic, results-driven, and entrepreneurial biotechnology executive with more than 20 years in the pharmaceutical and biotechnology industries. Combining her commercial experience with an understanding of the complexity of the U.S. and global markets (e.g., EMEAC, LATAM, Asia Pacific), Christina has been a key player on global teams involved in the launch and marketing of new products worldwide in roles of increasing leadership with Alexion Pharmaceuticals, Agilis Therapeutics and PTC Therapeutics. She is well-versed in global product commercialization, global shared medical services, and medical communications, with expertise in patient identification and diagnostic strategy.

Christina has a master’s degree in public health with a concentration in health policy and management from New York Medical College and a bachelor’s degree in biological science with a minor in applied design from The University of Vermont.

Jiamin is an accomplished professional with a diverse background spanning Ph.D. training, Wall Street equity research, and real-world commercial experience in both big pharma and small biotech. His journey includes roles as a business analyst at Decision Resource Group, catering to biopharma clients, and as an equity research associate at Guggenheim Invest Bank, delivering strategic insights to Wall Street investors. Jiamin has held various commercial positions at Takeda and bit.bio, a cell therapy biotech, where he played a crucial role in shaping commercial strategy for assets at various stages.

He is passionate about strategy development for drug candidates to optimize their potential for securing investors’ funding, identifying BD opportunities, and ultimately achieving commercial success in the market. Currently, he serves as the Weekly Newsletter Editor and orchestrates the BioVerse Webinar at ISWT-community. Jiamin holds a BS degree from Peking University, a Ph.D. from Mayo Clinic, and postgraduate training at Boston University and MIT.

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.